Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PROSTATE CANCER

Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?

Nature Reviews Urology volume 16, pages 335–336 (2019)Cite this article

Subjects

The PROSPER, SPARTAN, and ARAMIS trials demonstrated the efficacy of enzalutamide, apalutamide, and darolutamide, respectively, to extend metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer. However, questions remain regarding patient selection for these agents, particularly concerning adverse effects, patient PSA doubling time, and cost and formulary considerations.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Considerations when choosing a second-generation antiandrogen.

References

  1. Hussain, M. et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 378, 2465–2474 (2018).

    Article  CAS  Google Scholar 

  2. Smith, M. R. et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl. J. Med. 378, 1408–1418 (2018).

    Article  CAS  Google Scholar 

  3. Fizazi, K. et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 380, 1235–1246 (2019).

    Article  CAS  Google Scholar 

  4. Moilanen, A. M. et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci. Rep. 5, 12007 (2015).

    Article  Google Scholar 

  5. Scher, H. I. et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase1-2 study. Lancet 375, 1437–1446 (2010).

    Article  CAS  Google Scholar 

  6. Slovin, S. et al. Seizure rates in enzalutamide-treated men with metastatic castration-resistant prostate cancer and risk of seizure: the UPWARD study. JAMA Oncol. 24, 702–706 (2018).

    Article  Google Scholar 

  7. Ruiz Garcia, P. et al. Meta-analysis of randomized clinical trials in metastatic castration resistant prostate cancer: comparison of hypertension, neurological and psychiatric adverse events on enzalutamide and abiraterone acetate plus prednisone treatment [abstract]. Ann. Oncol. 27 (Suppl. 6), 738P (2016).

    Google Scholar 

  8. Smith, M. R. et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J. Clin. Oncol. 31, 3800–3806 (2013).

    Article  Google Scholar 

  9. Tombal, B. F. et al. Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials [abstract]. J. Clin. Oncol. 37 (Suppl. 7), 237 (2019).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Oncology, Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    Celestia Higano

Authors
  1. Celestia Higano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Celestia Higano.

Ethics declarations

Competing interests

The author declares that she has acted as a consultant for Bayer, Blue Earth Diagnostics, Clovis, Ferring, Hinova, and Janssen and has conducted research for Aragon, Astellas, AstraZeneca, Bayer, Emergent BioSolutions, Hoffman LaRoche, Medivation, and Pfizer.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Higano, C. Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?. Nat Rev Urol 16, 335–336 (2019). https://doi.org/10.1038/s41585-019-0186-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-019-0186-2

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing